TRAF3IP2 (E3 ubiquitin ligase TRAF3IP2) variants and mutations
TRAF3IP2 (also known as E3 ubiquitin ligase TRAF3IP2) is a human protein-coding gene encoding an e3 ubiquitin ligase protein. It connects IL-17 receptors to downstream NF-kappaB and MAPK signaling and is therefore central to barrier-tissue inflammatory responses. Pathogenic loss-of-function variants can cause chronic mucocutaneous candidiasis, while common variants influence psoriasis and related inflammatory disease. This analysis covers 307 TRAF3IP2 variants and mutations. Of these, 74% have computational variant effect predictions. Disease context includes Chronic mucocutaneous candidosis, psoriasis, and rheumatoid arthritis. Example TRAF3IP2 variants include N11D, P15L, and D19N.
Variant analysis overview
- Gene: TRAF3IP2
- Protein: E3 ubiquitin ligase TRAF3IP2
- UniProt accession: O43734
- Organism: Homo sapiens
- Variants analyzed: 307
- Variant scope: all variants
- Completed: 2026-08-21
Variant and mutation evidence
- Variant composition: 110 unspecified-consequence records; 1 stop lost; 1 stop retained variant; 117 missense variants; 15 frameshift variants; 56 synonymous variants; 6 stop-gained variants; 1 in-frame insertions; 2 splice-region variants
- Prediction scores: 228 variants have prediction scores (74% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Chronic mucocutaneous candidosis, psoriasis, rheumatoid arthritis, psoriasis vulgaris, psoriatic arthritis, type 2 diabetes mellitus, skin disorder, inflammatory bowel disease, neurodegenerative disease, chronic mucocutaneous candidiasis, autoimmune disease, discoid lupus erythematosus.
Protein structure and variant hotspots
- Protein features: 1 domains.
- Structural context: 187 variants have structural context.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable TRAF3IP2 variants
Examples include N11D, P15L, D19N, E20Q, S21L, Y24D, P25T, Q27*. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- N11D (p.Asn11Asp), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, Variant assessed as somatic; moderate impact.
- P15L (p.Pro15Leu), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, Variant assessed as somatic; moderate impact.
- D19N (p.Asp19Asn), rs33980500, ClinGen CA129379, cosmic curated COSV60675, ClinVar RCV000023605, AlphaMissense 0.38, MetaLR 0.24, Benign, Candidiasis, familial, 8; not specified
- E20Q (p.Glu20Gln), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, Variant assessed as somatic; moderate impact.
- S21L (p.Ser21Leu), rs758695030, NCI-TCGA Cosmic COSV6067, cosmic curated COSV60674, ExAC rs758695030, AlphaMissense 0.18, MetaLR 0.17, Variant assessed as somatic; moderate impact.
- Y24D (p.Tyr24Asp), rs2536183332, ClinGen CA365370348, ClinVar RCV002296166, Uncertain significance, Candidiasis, familial, 8
- P25T (p.Pro25Thr), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, Variant assessed as somatic; moderate impact.
- Q27* (p.Gln27Ter), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, Variant assessed as somatic; high impact.
- P37S (p.Pro37Ser), NCI-TCGA Cosmic COSV6067, cosmic curated COSV60677, REVEL 0.04, CADD 21.40, Uncertain significance, Candidiasis, familial, 8; not specified
- E40K (p.Glu40Lys), rs773041017, NCI-TCGA Cosmic COSV6067, cosmic curated COSV60676, ExAC rs773041017, AlphaMissense 0.08, MetaLR 0.04, Variant assessed as somatic; moderate impact.
- S41* (p.Ser41Ter), NCI-TCGA Cosmic COSV6067, Variant assessed as somatic; high impact.
- I48V (p.Ile48Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- M51V (p.Met51Val), rs2536182935, ClinGen CA365370022, ClinVar RCV002710697, Uncertain significance, Candidiasis, familial, 8
- A52S (p.Ala52Ser), NCI-TCGA Cosmic COSV6067, cosmic curated COSV60676, Variant assessed as somatic; moderate impact.
- S57F (p.Ser57Phe), rs2536182830, ClinGen CA365369925, ClinVar RCV004351732, REVEL 0.05, CADD 15.40, Uncertain significance, not specified
- T60A (p.Thr60Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L62I (p.Leu62Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- D68Y (p.Asp68Tyr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Q71E (p.Gln71Glu), NCI-TCGA Cosmic COSV6067, cosmic curated COSV60674, Variant assessed as somatic; moderate impact.
- H81Q (p.His81Gln), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, Variant assessed as somatic; moderate impact.
- R83W (p.Arg83Trp), rs13190932, ClinGen CA3963366, cosmic curated COSV60675, ClinVar RCV000455212, AlphaMissense 0.06, MetaLR 0.02, Benign, Candidiasis, familial, 8; not specified
- V85G (p.Val85Gly), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- R93C (p.Arg93Cys), rs376682410, ClinGen CA3963358, NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, AlphaMissense 0.10, MetaLR 0.07, Uncertain significance, Candidiasis, familial, 8; not specified
- R93H (p.Arg93His), rs141777182, ClinGen CA3963357, cosmic curated COSV60675, ClinVar RCV003115348, AlphaMissense 0.16, MetaLR 0.08, Uncertain significance, Candidiasis, familial, 8
- Q95P (p.Gln95Pro), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E98K (p.Glu98Lys), NCI-TCGA Cosmic COSV6067, cosmic curated COSV60677, Variant assessed as somatic; moderate impact.
- E98V (p.Glu98Val), NCI-TCGA Cosmic COSV6067, cosmic curated COSV60676, Variant assessed as somatic; moderate impact.
- E101Q (p.Glu101Gln), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- F104L (p.Phe104Leu), NCI-TCGA Cosmic COSV6067, cosmic curated COSV60675, Variant assessed as somatic; moderate impact.
- L111P (p.Leu111Pro), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- A114S (p.Ala114Ser), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, Variant assessed as somatic; moderate impact.
- S117F (p.Ser117Phe), NCI-TCGA Cosmic COSV6067, cosmic curated COSV60676, Variant assessed as somatic; moderate impact.
- A126E (p.Ala126Glu), rs893763256, ClinGen CA365368724, ClinVar RCV004315786, AlphaMissense 0.07, MetaLR 0.01, Likely benign, not specified
- V131A (p.Val131Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E137Q (p.Glu137Gln), rs2536181365, ClinGen CA365368465, ClinVar RCV004471115, Uncertain significance, not specified
- Q139P (p.Gln139Pro), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- F142L (p.Phe142Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- K145T (p.Lys145Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- R146H (p.Arg146His), rs1243216801, ClinGen CA365368179, NCI-TCGA Cosmic COSV6067, cosmic curated COSV60676, AlphaMissense 0.07, MetaLR 0.03, Uncertain significance, Candidiasis, familial, 8
- N147K (p.Asn147Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- Q148K (p.Gln148Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S155L (p.Ser155Leu), NCI-TCGA Cosmic COSV6067, cosmic curated COSV60675, Variant assessed as somatic; moderate impact.
- G162D (p.Gly162Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S165* (p.Ser165Ter), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, Variant assessed as somatic; high impact.
- P173L (p.Pro173Leu), NCI-TCGA Cosmic COSV6067, Variant assessed as somatic; high impact.
- N174K (p.Asn174Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- L180F (p.Leu180Phe), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, Variant assessed as somatic; moderate impact.
- E185D (p.Glu185Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- R196G (p.Arg196Gly), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- T206K (p.Thr206Lys), NCI-TCGA Cosmic COSV6067, cosmic curated COSV60676, Variant assessed as somatic; moderate impact.
- D214A (p.Asp214Ala), NCI-TCGA Cosmic COSV6067, cosmic curated COSV60675, Variant assessed as somatic; moderate impact.
- Q234E (p.Gln234Glu), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, Variant assessed as somatic; moderate impact.
- Q234K (p.Gln234Lys), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, Variant assessed as somatic; moderate impact.
- S242F (p.Ser242Phe), NCI-TCGA Cosmic COSV6067, cosmic curated COSV60675, Variant assessed as somatic; moderate impact.
- Q247* (p.Gln247Ter), NCI-TCGA Cosmic COSV6067, cosmic curated COSV60677, Variant assessed as somatic; high impact.
- Y253H (p.Tyr253His), NCI-TCGA Cosmic COSV6067, cosmic curated COSV60675, Variant assessed as somatic; moderate impact.
- P262T (p.Pro262Thr), NCI-TCGA Cosmic COSV6067, cosmic curated COSV60676, Variant assessed as somatic; moderate impact.
- N263T (p.Asn263Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L264F (p.Leu264Phe), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- P280S (p.Pro280Ser), rs2536178957, ClinGen CA365365588, ClinVar RCV003038574, Uncertain significance, Candidiasis, familial, 8
- H282Y (p.His282Tyr), NCI-TCGA Cosmic COSV6067, cosmic curated COSV60676, Variant assessed as somatic; moderate impact.
- R292* (p.Arg292Ter), rs774729962, NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, ExAC rs774729962, Variant assessed as somatic; high impact.
- Q296* (p.Gln296Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- Q300* (p.Gln300Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- H317N (p.His317Asn), NCI-TCGA Cosmic COSV6067, cosmic curated COSV60675, Variant assessed as somatic; moderate impact.
- P318L (p.Pro318Leu), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, REVEL 0.09, CADD 23.60, Variant assessed as somatic; moderate impact.
- H332Q (p.His332Gln), rs1043730, ClinGen CA3963219, cosmic curated COSV10741, ClinVar RCV000454545, AlphaMissense 0.05, MetaLR 0.00, Benign, Candidiasis, familial, 8; not specified
- P336S (p.Pro336Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- A337T (p.Ala337Thr), rs751906100, ClinGen CA3963216, NCI-TCGA Cosmic COSV6067, cosmic curated COSV60676, AlphaMissense 0.07, MetaLR 0.02, Uncertain significance, not specified; Candidiasis, familial, 8
- P344L (p.Pro344Leu), rs559874598, ClinGen CA3963213, ClinVar RCV002614880, 1000Genomes rs559874598, AlphaMissense 0.08, MetaLR 0.04, Uncertain significance, Candidiasis, familial, 8
- G345R (p.Gly345Arg), rs1796111146, ClinGen CA365362872, ClinVar RCV003032045, AlphaMissense 0.11, MetaLR 0.03, Uncertain significance, Candidiasis, familial, 8
- N359D (p.Asn359Asp), rs763843514, ExAC rs763843514, gnomAD rs763843514, AlphaMissense 0.07, MetaLR 0.02, Variant assessed as somatic; moderate impact.
- A385V (p.Ala385Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- R397K (p.Arg397Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- R397R (p.Arg397Arg), gnomAD 6-111572982-C-T, CADD 11.00
- R397Q (p.Arg397Gln), rs755224720, gnomAD 6-111572983-C-T, REVEL 0.29, CADD 34.00
- T402N (p.Thr402Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- T402S (p.Thr402Ser), gnomAD 6-111572968-G-C, REVEL 0.25, CADD 26.20
- S403S (p.Ser403Ser), rs761644425, gnomAD 6-111572961-C-T, CADD 5.56
- S403L (p.Ser403Leu), rs1419307347, gnomAD 6-111572962-G-A, REVEL 0.59, AlphaMissense 0.99
- E408* (p.Glu408Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- E408D (p.Glu408Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E408G (p.Glu408Gly), gnomAD 6-111572944-T-C, REVEL 0.49, CADD 33.00
- L409M (p.Leu409Met), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, Variant assessed as somatic; moderate impact.
- R410W (p.Arg410Trp), rs767596361, ClinGen CA365362425, NCI-TCGA Cosmic COSV6067, cosmic curated COSV60676, AlphaMissense 0.94, MetaLR 0.13, Uncertain significance, Candidiasis, familial, 8
- K411E (p.Lys411Glu), rs1253864619, gnomAD 6-111572936-T-C, REVEL 0.14, CADD 24.80
- V412L (p.Val412Leu), rs200053958, gnomAD 6-111572939-C-G, REVEL 0.07, CADD 17.40
- V412V (p.Val412Val), rs759181789, gnomAD 6-111572940-C-G, CADD 9.40
- V412M (p.Val412Met), gnomAD 6-111572942-C-T, REVEL 0.28, CADD 23.40
- V412A (p.Val412Ala), gnomAD 6-111572977-A-G, REVEL 0.44, CADD 27.60
- F413F (p.Phe413Phe), rs932934755, gnomAD 6-111572931-G-A, CADD 3.39
- F413C (p.Phe413Cys), gnomAD 6-111572932-A-C, REVEL 0.25, CADD 24.10
- F413Y (p.Phe413Tyr), gnomAD 6-111572932-A-T, REVEL 0.30, CADD 25.80
- T415T (p.Thr415Thr), gnomAD 6-111572952-T-C, CADD 11.70
- T415I (p.Thr415Ile), rs763896769, gnomAD 6-111572953-G-A, REVEL 0.38, CADD 27.40
- Y416Y (p.Tyr416Tyr), rs765112469, gnomAD 6-111572964-A-G, CADD 9.03
- S417L (p.Ser417Leu), rs1419307347, NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, NCI-TCGA Cosmic COSV6067, AlphaMissense 0.99, MetaLR 0.19, Variant assessed as somatic; moderate impact.
- M418T (p.Met418Thr), rs372899704, gnomAD 6-111572947-A-G, REVEL 0.04, CADD 17.10
- M418L (p.Met418Leu), rs774838745, gnomAD 6-111572948-T-A, REVEL 0.07, CADD 15.80
- M418V (p.Met418Val), rs774838745, gnomAD 6-111572948-T-C, REVEL 0.03, CADD 11.60
- A421A (p.Ala421Ala), rs1444561314, gnomAD 6-111572949-A-G, CADD 11.00
- V424V (p.Val424Val), rs1448625434, gnomAD 6-111572913-T-A, CADD 7.49
- V424L (p.Val424Leu), gnomAD 6-111572930-C-G, REVEL 0.28, CADD 23.80
- V424M (p.Val424Met), gnomAD 6-111572930-C-T, REVEL 0.34, CADD 26.00
- F427L (p.Phe427Leu), gnomAD 6-111572924-A-G, REVEL 0.20, CADD 24.60
- N429N (p.Asn429Asn), rs571096374, gnomAD 6-111572910-A-G, CADD 7.33
- L431W (p.Leu431Trp), gnomAD 6-111572916-CA-C, CADD 31.00
- L431L (p.Leu431Leu), rs1795874052, gnomAD 6-111572916-C-T, CADD 11.90
- L431S (p.Leu431Ser), rs1283590811, gnomAD 6-111572917-A-G, REVEL 0.17, AlphaMissense 0.32
- L431F (p.Leu431Phe), gnomAD 6-111572918-AC-A, CADD 27.40
- L432S (p.Leu432Ser), rs1283590811, NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, gnomAD rs1283590811, AlphaMissense 0.32, MetaLR 0.01, Variant assessed as somatic; moderate impact.
- G435G (p.Gly435Gly), gnomAD 6-111567663-G-T, CADD 8.31
- G435S (p.Gly435Ser), rs1315991109, gnomAD 6-111572909-C-T, REVEL 0.65, CADD 31.00
- F436F (p.Phe436Phe), gnomAD 6-111567681-A-G, CADD 11.70
- I440V (p.Ile440Val), gnomAD 6-111567671-T-C, REVEL 0.07, CADD 17.40
- I440T (p.Ile440Thr), gnomAD 6-111567685-A-G, REVEL 0.37, CADD 27.00
- I440M (p.Ile440Met), gnomAD 6-111567690-A-C, REVEL 0.26, CADD 23.60
- I440F (p.Ile440Phe), gnomAD 6-111567692-T-A, REVEL 0.35, CADD 32.00
- D441D (p.Asp441Asp), rs773421131, gnomAD 6-111567675-A-G, CADD 4.62
- D441A (p.Asp441Ala), rs1795697055, gnomAD 6-111567676-T-G, REVEL 0.15, CADD 26.90
- D441G (p.Asp441Gly), gnomAD 6-111567676-T-C, REVEL 0.14, CADD 25.30
- D441H (p.Asp441His), gnomAD 6-111567687-GTC-G, CADD 33.00
- D441V (p.Asp441Val), gnomAD 6-111567688-T-A, REVEL 0.73, CADD 28.30
- D441Y (p.Asp441Tyr), gnomAD 6-111567689-C-A, REVEL 0.61, CADD 28.20
- I442V (p.Ile442Val), rs375272521, cosmic curated COSV60676, ESP rs375272521, ExAC rs375272521, AlphaMissense 0.33, MetaLR 0.03, Variant assessed as somatic; moderate impact.
- I442I (p.Ile442Ile), rs1279834873, gnomAD 6-111567651-A-G, CADD 9.98
- I442T (p.Ile442Thr), rs1197932494, gnomAD 6-111567655-A-G, REVEL 0.09, CADD 23.60
- E444D (p.Glu444Asp), rs200991285, gnomAD 6-111567639-C-G, REVEL 0.22, CADD 22.30
- E444E (p.Glu444Glu), rs200991285, gnomAD 6-111567639-C-T, CADD 8.13
- E444K (p.Glu444Lys), rs747047346, gnomAD 6-111567641-C-T, REVEL 0.42, CADD 24.60
- R446I (p.Arg446Ile), NCI-TCGA Cosmic COSV6067, cosmic curated COSV60675, Variant assessed as somatic; moderate impact.
- R446K (p.Arg446Lys), NCI-TCGA Cosmic COSV6067, TOPMed rs1795696831, Variant assessed as somatic; moderate impact.
- R446Q (p.Arg446Gln), rs978486734, gnomAD 6-111567667-C-T, REVEL 0.21, CADD 25.00
- R446* (p.Arg446Ter), rs1245733568, gnomAD 6-111567668-G-A, CADD 38.00
- R448* (p.Arg448Ter), rs1245733568, NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, TOPMed rs1245733568, Variant assessed as somatic; high impact.
- R448M (p.Arg448Met), gnomAD 6-111567628-C-A, REVEL 0.13, CADD 24.20
- R448G (p.Arg448Gly), gnomAD 6-111567629-T-C, REVEL 0.09, CADD 21.20
- R448R (p.Arg448Arg), gnomAD 6-111567636-G-C, CADD 10.20
- R448H (p.Arg448His), rs1352832056, gnomAD 6-111567637-C-T, REVEL 0.26, AlphaMissense 0.17
- R448C (p.Arg448Cys), rs200246882, gnomAD 6-111567638-G-A, REVEL 0.28, CADD 29.90
- D451E (p.Asp451Glu), gnomAD 6-111567624-A-AT, CADD 33.00
- D451N (p.Asp451Asn), rs1331303188, gnomAD 6-111567626-C-T, REVEL 0.27, CADD 27.10
- I453I (p.Ile453Ile), rs371382152, gnomAD 6-111566543-G-A, CADD 10.90
- I453F (p.Ile453Phe), gnomAD 6-111566545-T-A, REVEL 0.51, CADD 29.00
- I453V (p.Ile453Val), gnomAD 6-111566545-T-C, REVEL 0.24, CADD 24.60
- I453T (p.Ile453Thr), gnomAD 6-111566547-A-G, REVEL 0.79, CADD 28.00
- K454K (p.Lys454Lys), rs768862486, gnomAD 6-111567648-T-C, CADD 9.57
- K454E (p.Lys454Glu), gnomAD 6-111567650-T-C, REVEL 0.12, CADD 24.00
- W455R (p.Trp455Arg), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, Variant assessed as somatic; moderate impact.
- W455* (p.Trp455Ter), gnomAD 6-111567645-C-T, CADD 39.00
- M456I (p.Met456Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- R458H (p.Arg458His), rs1352832056, ClinGen CA365361517, NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, AlphaMissense 0.17, MetaLR 0.10, Uncertain significance, Candidiasis, familial, 8
- R458L (p.Arg458Leu), NCI-TCGA Cosmic COSV1003, Variant assessed as somatic; moderate impact.
- Y459Y (p.Tyr459Tyr), rs1795694708, gnomAD 6-111567633-G-A, CADD 8.47
- Y459H (p.Tyr459His), gnomAD 6-111567635-A-G, REVEL 0.28, CADD 28.50
- L460F (p.Leu460Phe), gnomAD 6-111567632-G-A, REVEL 0.34, CADD 27.30
- D462E (p.Asp462Glu), rs150436455, gnomAD 6-111566513-G-T, REVEL 0.28, CADD 23.40
- D462D (p.Asp462Asp), rs150436455, gnomAD 6-111566513-G-A, CADD 10.60
- D462G (p.Asp462Gly), gnomAD 6-111566514-T-C, REVEL 0.45, CADD 32.00
- K463R (p.Lys463Arg), gnomAD 6-111566520-T-C, REVEL 0.25, CADD 25.30
- T464T (p.Thr464Thr), rs200213270, gnomAD 6-111566555-G-C, CADD 9.93
- T464A (p.Thr464Ala), rs1562419961, gnomAD 6-111566557-T-C, REVEL 0.16, CADD 24.50
- V465V (p.Val465Val), gnomAD 6-111566540-T-C, CADD 11.30
- V465A (p.Val465Ala), gnomAD 6-111566541-A-AGG, CADD 34.00
- V465L (p.Val465Leu), gnomAD 6-111566542-C-A, REVEL 0.18, CADD 22.70
- V465I (p.Val465Ile), rs775776262, gnomAD 6-111566542-C-T, REVEL 0.04, AlphaMissense 0.07
- V465M (p.Val465Met), rs1795642581, gnomAD 6-111566554-C-T, REVEL 0.16, CADD 25.90
- V469I (p.Val469Ile), rs775776262, ClinGen CA3963089, NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, AlphaMissense 0.07, MetaLR 0.01, Uncertain significance, not specified; Candidiasis, familial, 8
- V469M (p.Val469Met), rs1237812708, gnomAD 6-111566512-C-T, REVEL 0.31, AlphaMissense 0.92
- A470A (p.Ala470Ala), rs781159059, gnomAD 6-111566501-A-G, CADD 8.81
- A470T (p.Ala470Thr), rs111815306, gnomAD 6-111566503-C-T, REVEL 0.05, CADD 22.00
- A470L (p.Ala470Leu), gnomAD 6-111566503-CG-C, CADD 29.30
- S472S (p.Ser472Ser), rs771161608, gnomAD 6-111566495-C-T, CADD 12.60
- S472L (p.Ser472Leu), rs367784420, gnomAD 6-111566496-G-A, REVEL 0.14, CADD 23.80
- S472P (p.Ser472Pro), rs1240987623, gnomAD 6-111566497-A-G, REVEL 0.05, CADD 22.90
- P473P (p.Pro473Pro), rs1180041195, gnomAD 6-111566528-G-A, CADD 13.20
- P473S (p.Pro473Ser), rs1795641658, gnomAD 6-111566530-G-A, REVEL 0.53, CADD 27.50
- K476R (p.Lys476Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Q477H (p.Gln477His), gnomAD 6-111566492-C-A, REVEL 0.24, CADD 24.80
- D478G (p.Asp478Gly), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10038, REVEL 0.23, CADD 26.60, Variant assessed as somatic; moderate impact.
Public TRAF3IP2 analysis runs
- TRAF3IP2 analysis run — TRAF3IP2 (307 variants) — completed 2026-08-21